This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

ICN Pharma Looks Set to Acquire Ribapharm

With just a few hours until deadline, it would appear that ICN Pharmaceuticals (ICN) will complete its acquisition of Ribapharm (RNA) in a deal that has been as contentious as it is unusual.

Shareholders of Ribapharm have until 5 p.m. EDT to tender shares to ICN for $6.25 per share in cash, an increase from ICN's original cash tender bid of $5.60 announced in June. The offer is for the approximately 20% of Ribapharm shares that ICN doesn't already own.

Neither company would discuss the progress of the cash tender offer; but judging from trading in Ribapharm's stock, it would take a dramatic last-minute surprise for the transaction to fail.

Since ICN raised its offer on Aug. 4, Ribapharm's stock has barely budged, with closing prices hovering between $6.14 and $6.17 a share. In midday trading Tuesday, the stock was at $6.18.

The higher price came with a caveat: Ribapharm agreed to drop a poison pill, originally designed to kick in if a suitor acquired more than 89.9% of its shares.

In return, Ribapharm, whose board still calls ICN's offer "inadequate," agreed to let the deal go through if two-thirds of Ribapharm's shareholders accepted the improved offer. When ICN raised its buyout offer, it said 53% of Ribapharm shareholders had accepted the cash tender offer at the original price.

ICN and Ribapharm are both based in Costa Mesa, Calif. ICN spun off Ribapharm in April 2002 while retaining about 83% of the spinoff's shares. ICN originally said it would distribute the rest of the shares to Ribapharm shareholders within six months of the IPO. The IPO price was $10 a share.

All of Ribapharm's revenue comes from royalties from the drug ribavirin that it licenses to Schering-Plough and Hoffmann La Roche. ICN's sales reflect a mixture of ribavirin royalties as well as many other drugs.

ICN also reported last week that it had reached an agreement in principle to settle six lawsuits filed by Ribapharm shareholders who alleged ICN had "breached its fiduciary duties" as the controlling shareholder in Ribapharm relating to the original cash tender offer. No details were given for the agreement that was reached Aug. 4. A seventh lawsuit is still pending; all of the cases were filed in the Delaware Court of Chancery. A similar lawsuit is pending in California.

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs